Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05671991 · ClinicalTrials.gov registry record · Phase 4
Effect of Empagliflozin on Peritoneal and Kidney Function in End Stage Renal Disease
A Phase 4 study of End Stage Renal Disease on Dialysis, sponsored by Yale University.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT05671991: Recruiting Phase 4 study of End Stage Renal Disease on Dialysis, sponsored by Yale University.
NCT05671991 is a Phase 4 study of End Stage Renal Disease on Dialysis that is actively recruiting participants, run by Yale University. The registered enrollment target is 30 participants, below the 74-participant average among 9 other End Stage Renal Disease on Dialysis trials with a reported enrollment target (59% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05671991, a Phase 4 study of End Stage Renal Disease on Dialysis, is actively recruiting participants, sponsored by Yale University.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The main purpose of the study is to determine if empagliflozin can reduce peritoneal glucose absorption in patients with end stage renal diease (ESRD) on peritoneal dialysis. This is a randomized, placebo controlled, acute crossover study of empagliflozin in an anticipated 30 chronic PD patients, with an 8 week "pre post" open label extension in all 30 patients where they will receive empagliflozin daily.
Primary Outcome
Total glucose absorption in grams with empagliflozin vs. placebo
Conditions Studied
Interventions
- DRUG Empagliflozin 10 MG
- DRUG Empagliflozin 25 mg vs Placebo
Study Locations (1)
Connecticut
- Yale University - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2023-03-01 |
| Est. Completion | 2026-06-30 |
| Phase | Phase 4 |
What NCT05671991 shows while recruiting
NCT05671991 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 74-participant average among 9 other End Stage Renal Disease on Dialysis trials with a reported enrollment target (59% lower).
The record links to 1 condition, with End Stage Renal Disease on Dialysis appearing as the primary indexed condition, and to 2 interventions - of which Empagliflozin 10 MG is the first listed.
NCT05671991 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT05671991 about?
NCT05671991 is a clinical study titled "Effect of Empagliflozin on Peritoneal and Kidney Function in End Stage Renal Disease". The main purpose of the study is to determine if empagliflozin can reduce peritoneal glucose absorption in patients with end stage renal diease (ESRD) on peritoneal dialysis. This is a randomized, placebo controlled, acute crossover study of empagliflozin in an anticipated 30 chronic PD patients, w...
What is the current status of trial NCT05671991?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 30 participants. The study started on 2023-03-01. Estimated completion is 2026-06-30.
What conditions does trial NCT05671991 study?
This clinical trial studies the following conditions: End Stage Renal Disease on Dialysis.
What interventions are being tested in trial NCT05671991?
The interventions under investigation include: Empagliflozin 10 MG (DRUG), Empagliflozin 25 mg vs Placebo (DRUG).
Who is sponsoring clinical trial NCT05671991?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05671991 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for End Stage Renal Disease on Dialysis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05671991's enrollment target sits among peer trials
30 8th of 9 higher than 1 of 9 other End Stage Renal Disease on Dialysis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other End Stage Renal Disease on Dialysis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
DIALYSIS-TIR Study
ACTIVE NOT RECRUITING · Phase 4
-
Fight Fatigue: A Progressive Muscle Relaxation and Walking Intervention to Reduce Fatigue in Adults With ESKD
RECRUITING · NA
-
Comparing Surgical and Endovascular Arteriovenous Fistula Creation
RECRUITING · NA
-
The Home Blood Pressure (BP) Trial
ACTIVE NOT RECRUITING · NA
-
MoVE Trial: Motivational Strategies to Empower African Americans to Improve Dialysis Adherence
ACTIVE NOT RECRUITING · NA
-
Motivational Strategies To Empower African Americans To Improve Dialysis Adherence
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI